Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT06183671

JX09 SAD/MAD in Healthy Participants

Conditions: Resistant Hypertension

Sex: All
Ages: 18 Years – 55 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 92
Sponsor: Ji Xing Pharmaceuticals Australia Pty Ltd

Location: Nucleus Network Pty Ltd Melbourne Melbourne

Summary

This is a phase 1, randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose study in healthy adult to test the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of JX09 when administered to healthy adult subjects.

Eligibility Criteria

Inclusion Criteria: * Male or female aged 18 to 55 years (inclusive) * In good health as deemed by the Investigator through a medical evaluation, including medical history, physical examination, and laboratory tests * Body mass index (BMI) between 18 and 32 kg/m2, with a minimum weight of 50 kg at Screening Exclusion Criteria: * Clinically significant oncologic, infectious, cardiovascular, pulmonary, hepatic, gastrointestinal, hematologic, metabolic, endocrine, neurologic, immunologic, renal, psychiatric, or other condition that in the opinion of the Investigator or Medical Monitor would make is unsafe for the participant to join the study or fulfill its requirements. * A clinical abnormality or abnormal laboratory parameter(s) in the opinion of the Investigator or Medical Monitor is likely to introduce additional risk or will affect data interpretation. * Postural tachycardia or hypotension. * Female of childbearing potential who is pregnant, lactating, or planning to become pregnant.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06183671). StuddyBuddy aggregates publicly available trial information.